JP5886326B2 - 三環式キナーゼ阻害薬 - Google Patents

三環式キナーゼ阻害薬 Download PDF

Info

Publication number
JP5886326B2
JP5886326B2 JP2013556755A JP2013556755A JP5886326B2 JP 5886326 B2 JP5886326 B2 JP 5886326B2 JP 2013556755 A JP2013556755 A JP 2013556755A JP 2013556755 A JP2013556755 A JP 2013556755A JP 5886326 B2 JP5886326 B2 JP 5886326B2
Authority
JP
Japan
Prior art keywords
pyrimido
amino
imidazo
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013556755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506929A (ja
JP2014506929A5 (enExample
Inventor
トン,ユンソン
ペニング,トーマス・デイー
フロールジヤンシツク,アラン
ミヤシロ,ジユリー
ウツズ,キース・ダブリユ
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2014506929A publication Critical patent/JP2014506929A/ja
Publication of JP2014506929A5 publication Critical patent/JP2014506929A5/ja
Application granted granted Critical
Publication of JP5886326B2 publication Critical patent/JP5886326B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2013556755A 2011-02-28 2012-02-27 三環式キナーゼ阻害薬 Expired - Fee Related JP5886326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28
US61/447,405 2011-02-28
PCT/US2012/026685 WO2012161812A1 (en) 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases

Publications (3)

Publication Number Publication Date
JP2014506929A JP2014506929A (ja) 2014-03-20
JP2014506929A5 JP2014506929A5 (enExample) 2015-04-16
JP5886326B2 true JP5886326B2 (ja) 2016-03-16

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013556755A Expired - Fee Related JP5886326B2 (ja) 2011-02-28 2012-02-27 三環式キナーゼ阻害薬

Country Status (11)

Country Link
US (1) US8710065B2 (enExample)
EP (1) EP2681221B1 (enExample)
JP (1) JP5886326B2 (enExample)
CN (1) CN103703005A (enExample)
AR (1) AR085502A1 (enExample)
CA (1) CA2827648A1 (enExample)
ES (1) ES2587514T3 (enExample)
MX (1) MX340402B (enExample)
TW (1) TWI532742B (enExample)
UY (1) UY33925A (enExample)
WO (1) WO2012161812A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS61089B1 (sr) 2012-06-13 2020-12-31 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
WO2015154191A1 (en) * 2014-04-10 2015-10-15 Dalhousie University Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN109906227B (zh) * 2016-11-16 2022-03-11 上海瑛派药业有限公司 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
CA3071795A1 (en) 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
PL3712150T3 (pl) 2017-11-01 2024-09-02 Wuxi Biocity Biopharmaceutics Co., Ltd. Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowania
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020083404A1 (zh) 2018-10-26 2020-04-30 南京明德新药研发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CA3128293A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
PT3964510T (pt) 2019-04-30 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina do composto inibidor de wee1 e sua utilização
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4013750A1 (en) 2019-08-14 2022-06-22 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202516803A (en) 2019-10-11 2025-10-10 Incyte Corp Bicyclic amines as cdk2 inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114502559B (zh) * 2019-10-16 2024-02-02 上海瑛派药业有限公司 二氢咪唑并嘧啶并嘧啶酮类化合物
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7796674B2 (ja) 2020-06-17 2026-01-09 ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド Wee-1阻害剤としてのピラゾロ[3,4-d]ピリミジン-3-オン誘導体
US20240182447A1 (en) * 2021-02-19 2024-06-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
BR112023022236A2 (pt) * 2021-04-30 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US20250049798A1 (en) * 2021-11-09 2025-02-13 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534990A1 (en) 2003-07-25 2005-02-10 Novartis Ag P-38 kinase inhibitors
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
CN101553491B (zh) * 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
AU2009325398A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
EP2681221B1 (en) 2016-05-18
MX340402B (es) 2016-07-07
AR085502A1 (es) 2013-10-09
CA2827648A1 (en) 2012-11-29
TWI532742B (zh) 2016-05-11
CN103703005A (zh) 2014-04-02
ES2587514T3 (es) 2016-10-25
JP2014506929A (ja) 2014-03-20
EP2681221A1 (en) 2014-01-08
UY33925A (es) 2012-09-28
WO2012161812A1 (en) 2012-11-29
US8710065B2 (en) 2014-04-29
US20120220572A1 (en) 2012-08-30
TW201247675A (en) 2012-12-01
MX2013009873A (es) 2014-03-12

Similar Documents

Publication Publication Date Title
JP5886326B2 (ja) 三環式キナーゼ阻害薬
US8796289B2 (en) Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
EP2454257B1 (en) Pyrrolopyridine inhibitors of kinases
EP2569316B1 (en) Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
US9181239B2 (en) Pyridopyrimidinone inhibitors of kinases
EP3288931B2 (en) Certain protein kinase inhibitor
JP2014520855A (ja) 増殖性疾患の治療に有用な三環式キナーゼ阻害薬
JP2013525304A (ja) ピロロピラジノン系キナーゼ阻害薬
HK1196370A (en) Tricyclic inhibitors of kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160210

R150 Certificate of patent or registration of utility model

Ref document number: 5886326

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees